NEW YORK, NY / ACCESSWIRE / January 30, 2017 / The following statement is being issued by Levi & Korsinsky, LLP:

To: All persons or entities who purchased or otherwise acquired American Depositary Receipts of Novo Nordisk A/S (NYSE: NVO) between February 5, 2015 and October 27, 2016.

You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the District of New Jersey. To get more information go to: http://www.zlk.com/pslra/novo-nordisk-as, or contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.

The complaint alleges that during the Class Period, Novo Nordisk issued materially false and misleading earnings and forecasts; said reports were inflated by collusive price fixing concerning the Company’s insulin drugs. The complaint further alleges that the Company misrepresented and concealed the true extent of the pricing pressures it was experiencing from pharmacy benefit managers.

If you suffered a loss in Novo Nordisk, you have until March 13, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
30 Broad Street – 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

ReleaseID: 453813

NEW YORK, NY / ACCESSWRE / January 30, 2017 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against PayPal Holdings, Inc. (“PayPal” or the “Company”) (NASDAQ: PYPL), eBay, Inc. (“eBay”) (NASDAQ: EBAY), and certain of its officers, and is on behalf of a class consisting of all persons or entities who: (1) purchased or otherwise acquired eBay securities on the open market on or after December 19, 2013 (the “eBay Class Period”) and subsequently received PayPal securities pursuant to eBay’s spin-off of PayPal, effective as of July 17, 2015; and/or (2) purchased or otherwise acquired PayPal securities on the open market between July 20, 2015 and April 28, 2016, both dates inclusive (the “PayPal Class Period” and, together with the eBay Class Period, the “Class Period”). Such investors are advised to join this case by visiting the firm’s site: http://www.bgandg.com/pypl.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).

PayPal, spun off from eBay in July 2015, is an American technology platform company running a worldwide online payments system that enables digital and mobile payments on behalf of consumers and merchants. Between 2002 and 2015, PayPal functioned as a subsidiary of eBay. eBay is an American multinational corporation and e-commerce company offering consumer-to-consumer and business-to-consumer payment solutions online.

In 2013, PayPal acquired Braintree, a payment service provider and holder of Venmo. Defining itself as a “digital wallet,” Venmo is a mobile payment service that allows its users to transfer money to each other after setting up a personal Venmo account and linking it to users’ bank accounts.

On September 30, 2014, eBay publicized that it would spin off PayPal and its services, including Venmo, into a separate publicly traded company. The spin off was completed pursuant to which each holder of eBay common stock received one share of PayPal common stock for every share of eBay held at July 8, 2015’s market close.

The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about its business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (1) PayPal’s Venmo service was involved in unfair trade practices; (2) once the above facts were made public, it was likely to impact PayPal’s profitability of its Venmo service and increase regulatory scrutiny; and/or (3) consequently, PayPal’s public statements were materially false and misleading at all relevant times.

On April 28, 2016, PayPal Holdings Inc. announced that federal regulators are investigating its Venmo free peer-to-peer payment service in relation with possible unfair trade practices. PayPal received a civil investigative demand on March 28 from the Federal Trade Commission (the “FTC”) for Venmo documents. The FTC review concentrates on whether PayPal, through Venmo, engaged in unfair or deceptive trade practices. The investigation “may result in substantial costs, including legal fees, fines, penalties and remediation expenses and actions and require us to change aspects of the manner in which we operate Venmo.” Following this news, PayPal stock dropped $0.89 per share or 2.22% and closed at $39.18 on April 29, 2016.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm’s site: http://www.bgandg.com/pypl, or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in PayPal, you have until February 27, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC

Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 451946

NEW YORK, NY / ACCESSWIRE / January 30, 2017 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Abeona Therapeutics Inc. (“Abeona” or the “Company”) (NASDAQ: ABEO) and certain of its officers, and is on behalf of purchasers of: (1) PlasmaTech Biopharmaceuticals, Inc. securities from March 31, 2015 through June 19, 2015, both dates inclusive (the “PlasmaTech Class Period”); and/or (2) Abeona Therapeutics Inc. securities from June 22, 2015 through December 9, 2016, both dates inclusive (the “Abeona Class Period” and together with the PlasmaTech Class Period, the “Class Period”). Such investors are advised to join this case by visiting the firm’s site: http://www.bgandg.com/abeo.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements and/or failed to disclose that: (1) Abeona’s science in its proposed gene therapy treatment for Sanfilippo syndrome is unviable; (2) Steven H. Rouhandeh, Abeona’s Executive Chairman and Principal Executive Officer, previously worked in a high ranking position for a biotech promoter who was convicted of securities fraud and involved in manipulating biotech stocks; and (3) consequently, Abeona’s statements about its business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

On December 12, 2016, Mako Research reported on SeekingAlpha.com that “ABEO science is demonstrably unviable with numerous irrefutable flaws that will lead to failure.” Mako
Research also revealed that Steven H. Rouhandeh, Abeona’s Executive Chairman and Principal Executive Officer, was a former managing director at D. Blech & Co. brokerage firm, which was the subject of a SEC investigation in the 1990s, and a securities class action that reached $15 million settlement for investors, based on allegations that D. Blech & Co artificially manipulated the price of various biotech stocks and maintained the market price of the biotech stocks to keep its company’s interest in the stocks afloat. Following this news, Abeona stock dropped $0.70 per share or over 13% from its previous closing price to close at $4.45 per share on December 12, 2016.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm’s site: http://www.bgandg.com/abeo, or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Abeona, you have until February
14, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC

Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 451365

BioSSL Wins the Sesames Awards for Best Cybersecurity Solution from Trustech 2016 and the Silver Award for Best Biometric Solution from Fintech Finance

ACCESSWIRE / WELLINGTON, UNITED KINGDOM / JANUARY 30, 2017 / BioSSL wins the precious Sesames Award Trustech 2016 for best Cybersecurity Solution.

As one of the 3 finalists in the Cybersecurity category at Trustech 2016 in Cannes, France, BioSSL won the precious Sesames Award.

“We thank the Sesames Award jury, represented by Frazier Evans, Payments Director Booz Allen Hamilton, Nathan Hilt, Director Payments PriceWaterhouseCooper, Al Pascual, SVP, Research Director and Head of Fraud & Security Javelin Strategy & Research, Kevin Gillick, Executive Director GlobalPlatform, John Devlin, Principal Analyst and Founder P.A.ID Strategies, Max Snijder, CEO European Biometrics Group, as well as the organisers of Trustech (formerly Cartes).”

“We thank John Devlin, appointed as our personal coach and advisor by Trustech to lead us. We also thank our board member, Stephan Apel, and our South African partner, Gawie Keyser, for their presence and support at the booth and last, but not least, our lead investors and our dedicated development team. BioSSL changes the perception of the use of biometrics in cybersecurity and how to completely secure a user’s identity in the online world.”

Silver Award for Best Biometric Solution

Quote Finance Fintech:

“By using three human verification pathways – fingerprint, voice, and facial recognition – web security expert BioSSL locks down access to hackers. Its unique feature is that it does not allow for the storage of images, scans, or biometric features on a local device or server, thereby preserving their integrity if the device is stolen, damaged, or lost. BioSSL’s fingerprint and facial recognition template cannot be reverse engineered. Security is entirely handled on the BioSSL server and no two private-public keys are ever the same. The company is an omni-channel solution for banks, financial institutions, e-commerce, and government, using military-grade ID systems.”

SOURCE: BioSSL

ReleaseID: 453805

NEW YORK, NY / ACCESSWIRE / January 30, 2017 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against New Oriental Education & Technology Group Inc. (“New Oriental” or the “Company”) (NYSE: EDU) and certain of its officers, and is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired New Oriental American Depositary Receipts (“ADRs”) between September 27, 2016 and December 1, 2016, inclusive (the “Class Period”). Such investors are advised to join this case by visiting the firm’s site: http://www.bgandg.com/edu.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).

The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (1) New Oriental engaged in college application fraud; and (2) consequently, New Oriental’s statements about its business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

On December 2, 2016, Reuters reported that New Oriental has been accused of college application fraud. The report describes how New Oriental engaged in “writing application essays and teacher recommendations, and falsifying high school transcripts.” Reuters also said that the American International Recruitment Council (AIRC) “will investigate the company in response to the report,” and that the AIRC’s president-elect said the allegations were “highly concerning.” Following this news, New Oriental stock dropped $6.99 per share, or 14.27%, to close at $42.00 on December 2, 2016.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm’s site: http://www.bgandg.com/edu, or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in New Oriental, you have until February 13, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC

Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 451358

NEW YORK, NY / ACCESSWIRE / January 30, 2017 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against of Universal Health Services, Inc. (“Universal Health” or the “Company”) (NYSE: UHS) and certain of its officers, and is on behalf of a class consisting of all persons or entities who purchased Universal Health securities from February 26, 2015 through December 7, 2016, both dates inclusive (the “Class Period”). Such investors are advised to join this case by visiting the firm’s site: http://www.bgandg.com/uhs.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).

The Complaint alleges that throughout the Class Period Defendants made false and/or misleading statements and/or failed to disclose that: (1) Universal Health admitted patients based on its own financial considerations and not the patient’s medical needs; (2) Universal Health would keep patients admitted until their insurance payments ran out in order to bill for the maximum of its services; (3) accordingly, Universal Health’s revenues from inpatient care relied on unjustifiable practices; (4) due to the aforementioned, Universal Health lacked efficient internal control regarding its practices and policies of admitting patients; and (5) consequently, Universal Health’s public statements were materially false and misleading at all relevant times.

On December 7, 2016 Buzzfeed released its investigation into Universal Health “…based on interviews with 175 current and former UHS staff, including 18 executives who ran UHS hospitals; more than 120 additional interviews with patients, government investigators, and other experts; and a cache of internal documents.” Buzzfeed reported that “[c]urrent and former employees from at least 10 UHS hospitals in nine states said they were under pressure to fill beds by almost any method – which sometimes meant exaggerating people’s symptoms or twisting their words to make them seem suicidal – and to hold them until their insurance payments ran out.” Following this news, Universal Health stock dropped $15.01 per share or nearly 12% to close at $111.36 on December 7, 2016.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm’s site: http://www.bgandg.com/uhs, or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Universal Health, you have until February 21, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 451955

In an Interview with CEOCFO, Mark Sieczkarek, CEO of NovaBay Pharmaceuticals, Explains Why the Company is on a Path to Success in the Eye Care Market

AUSTIN, TX / ACCESSWIRE / January 30, 2017 / CEOCFO Magazine, an independent investment publication that highlights important technologies and companies, today released an interview [http://ceocfointerviews.com/interviews/NovaBayPharmaceuticals17.htm] with Mark M. Sieczkarek, Chairman and CEO of NovaBay®
Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on commercializing prescription
Avenova® lid and lash hygiene for the domestic eye care market.

In the interview, Mr. Sieczkarek described how NovaBay is helping patients and seeing rapid revenue growth in a large, relatively untapped segment of the ophthalmology market.

“We have a positive outlook for double-digit revenue growth in 2017,” he told CEOCFO
Magazine’s Bud Wayne. “We have a proven track record of increasing Avenova sales and a strategy that targets high-margin business. Our plan is to continue growing revenue as we focus on building shareholder value.”

“The key to NovaBay’ success was a change in strategy in late 2015,” said Mr. Sieczkarek. At the time, NovaBay was developing several products, “But I recognized an exciting opportunity to commercialize a unique product, Avenova® lid and lash hygiene, in a market that we estimate at 41 million Americans,” Mr. Sieczkarek explained. He directed NovaBay’s resources to its commercial operations and hired a sales force with experience selling ophthalmology products.

Last year, NovaBay raised $20 million through “friendly transactions” mainly with previous investors, and “I also made a significant investment of my own funds as a demonstration of my conviction,” said Mr. Sieczkarek.

The strategy is paying off, with sales expected to be up 146 percent in the fourth quarter of 2016 over the prior year. “We ended 2016 with $9.5 million in cash, our highest cash balance in two years,” said Mr. Sieczkarek.

Avenova is the only eye care product that contains NovaBay’s proprietary, stable and pure form of hypochlorous acid, called Neutrox. Neutrox “has shown potent antimicrobial action and neutralizes bacterial toxins,” Mr. Sieczkarek explained. “It is ideal for managing chronic conditions such as blepharitis and dry eye, as well as for pre- and post-use in eye surgeries.”

Doctors and patients report that with twice per day simple lid and lash cleansing, Avenova can bring relief from symptoms of those chronic conditions in as little as two weeks. In addition, with Avenova’s success, the company has been able to attract key opinion leaders in the ophthalmic and optometric communities as advisors. “Many of our advisors have issued their own press
releases featuring observations from Avenova use by their patients,” said Mr. Sieczkarek.

“While Avenova is by far the company’s largest revenue producer, NovaBay has other products,” Mr. Sieczkarek added. “The company has two additional commercial products based on Neutrox, NeutroPhase® Skin and Wound Cleanser for wound care with a proven track record as adjuvant treatment for devastating “flesh eating disease” and CelleRx® cleanser for various skin and cosmetic procedures.”

In addition, NovaBay has a second technology called Aganocides ® with a lead compound called Auriclosene®. “Auriclosene is a patented, synthetic molecule with a broad spectrum of activity against bacteria, viruses and fungi,” explained Mr. Sieczkarek. Clinical trials show that it has great potential to prevent urinary catheter blockage and encrustation, a problem that affects an estimated 100,000 patients in the U.S. with indwelling catheters and represents a potential annual market of more than $700 million. Mr. Sieczkarek added, “We are activity pursuing licensing, partnering and other transactions to monetize this and other non-core assets to further support Avenova commercialization.”

Contact:

Bud Wayne
Editorial Executive
CEOCFO Magazine
budwayne@ceocfomagazine.com

SOURCE: CEOCFO Magazine

ReleaseID: 453799

LOS ANGELES, CA / ACCESSWIRE / January 30, 2017 / When Time Inc. (NYSE: TIME) acquired Viant, a data-centric marketing company, last year, many observers wondered just how it planned on monetizing the 1 billion plus, strong registered user database, but its recently announced plans to acquire Adelphic just filled in the gaps.

Adelphic is an innovative demand-side platform (DSP) cross-channel programmatic advertising platform provider, which includes self-service media planning and execution tools.

The plan is to create the industry’s first “people-based demand-side platform” by strengthening Adelphic’s self-service programmatic proficiencies with Viant’s people-based offerings and, in this case, it just happens that this DSP is able to reach more than 1 billion global shoppers.

Programmatic digital advertising is projected to continue its rapid growth rate, which, according to eMarketer, should account for more than 70 percent of digital advertising.

The growth trends have benefited other companies, like Social Reality, Inc. (NASDAQ: SRAX), an Internet advertising and technology platform that provides tools to automate the digital advertising market, which just released certain preliminary unaudited operating results, as well as updated its 2016 and 2017 guidance.

Social Reality revamped their model last year to increase higher margin customer exposure and focus sales efforts on new products to attract advertisers with greater long term profitability potential. The strategic shift initially reduced revenues between the second and fourth quarters of 2016 by moving away from some of its SRAX buy-side clients who historically generated low gross margin, but revenues are already trending back towards historical averages.

By providing greater value to SRAX sell-side and SRAXmd clients, Social Reality grew their unaudited fourth quarter 2016 gross revenues to $11.5 million, a 41% increase over the 2015 same quarter, and a 20% increase over the previous quarter, resulting in unaudited gross profit of $4.7 million, an 86% increase over the third quarter of 2016.

Additionally, Social Reality announced a successful $4 million equity offering in January 2017, which they used to repay all its senior secured debt. Plus, its SRAXmd product line, the Company’s healthcare-focused programmatic RTB exchange that allows pharma brands and publishers of medical content to create custom exchanges that invite specific advertisers to bid on inventory on their sites, experienced record activity, with unaudited sales up 115% in 2016 and January 2017 accrued bookings up over 100%.

Social Reality’s management expects 2017 total revenues to reach the $45-$50 million range, resulting in $2-$5 million adjusted EBITDA. The greater long term profitability potential is a central reason that a ROTH Capital Partners’ analyst raised Social Reality’s EPS projections from $0.27 to $0.57 and placed a $9.25 price target on Social Reality.

It seems that the recent slew of deals was kick started in 2016 by a number of Chinese companies buying up ad tech properties, like the purchase of Media.net last August by a group of Chinese investors for $900 million in cash.

Time’s Adelphic acquisition follows Adobe Systems’ purchase of TubeMogul for $540 million, announced in August 2016 and closed in December. According to their press release, “Adobe’s acquisition of TubeMogul will create the first end-to-end independent advertising and data management solution that spans TV and digital formats, simplifying what has been a complex and fragmented process for the world’s biggest brands.”

We’re still a far cry from the number of high profile deals in 2014, like Facebook’s acquisition of LiveRail for a reported $400 million, Google’s Adometry and Spider.io acquisitions, as well as Yahoo acquiring BrightRoll for $640 million and Flurry for $200 million, but the Adelphic deal may help to usher in the next ad tech consolidation move.

DISCLAIMER: Access-WallStreet.com (AWS) is a third party publisher and news dissemination service provider that produces regular sponsored and non-sponsored reports, articles, stock market blogs, and newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS is NOT a registered broker/dealer/analyst/adviser, holds no investment licenses, and AWS’ market updates, news alerts, and corporate profiles are NOT a solicitation or recommendation to buy, sell, or hold securities. AWS will not be buying, selling, or trading in any of the above listed stocks during the publication of this report.

The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and based on publicly available information which is believed to be reliable. The included information is subject to change without notice. AWS is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may,” “future,” “plan,” or “planned,” “will,” or “should,” “expected,” “anticipates,” “draft,” “eventually,” or “projected.” You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and MSC undertakes no obligation to update such statements.

CONTACT:

ben@access-wallstreet.com

SOURCE: Access Wallstreet

ReleaseID: 453803

NEW YORK, NY / ACCESSWIRE / January 30, 2017 / The Biotech Industry witnessed a drop in mergers and acquisitions (M&A) activity amidst a slump in 2016. The Nasdaq Biotech Index declined roughly 22 percent in 2016. M&A activity within the Biotech Industry totaled 326 deals worth approximately $91 billion in 2016, compared to $118 billion the year prior, according to Bloomberg. Also the number of M&A deals in the sector in 2016 was the lowest total in six years. Research & development productivity of 12 of the biggest biopharma companies, which was measured by annual projected R&D returns, hit a 7 year low in 2016, according to a recent study completed by Deloitte. With many large firms having more cash available, giving them plenty of firepower for larger number of in M&A activities in 2017.

Register with us now
for your free membership and gain access to our latest research reports at: RDInvesting.com

“With a large gap remaining between large BioPharma’s actual and desired revenues, and historically high amounts of cash on hand, look for an uptick of larger acquisition targets,” says David Risinger, an analyst for Morgan Stanley who covers big pharma. “This is particularly true of the U.S. BioPharma industry, where the amount of cash on hand is greater and intentions more focused.”

Tenax Therapeutics Inc. (NASDAQ: TENX)

Get Your Up-To-Date Tenax Therapeutics
Research Report Click Here

Tenax Therapeutics’ shares spiked 19.34 percent to close at $2.16 a share Friday. The stock traded between $1.75 and $2.22 on volume of 1.84 million shares traded. Tenax’s development portfolio includes novel product candidates that have the potential to address various critical care conditions with high unmet medical need. The company is currently developing levosimendan in North America for the reduction in morbidly and mortality of cardiac surgery patients at risk of low cardiac output syndrome. Levosimendan has been granted the Fast Track designation by the U.S. Food and Drug Adminsitration.

ZIOPHARM Oncology Inc. (NASDAQ: ZIOP)

Get Your Up-To-Date ZIOPHARM Oncology
Research Report Click Here

ZIOPHARM Oncology’s shares jumped 5.47 percent to close at $5.78 a share Friday. The stock traded between $5.48 and $5.79 on volume of 1.13 million shares traded. On January 10th, the company and Intrexon Corp. announced the signing of a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) for the development of adoptive cell transfer (ACT)-based immunotherapies genetically modified using the Sleeping Beauty (SB) transposon/transposase system to express T-cell receptors (TCRs) for the treatment of solid tumors.

“Treating liquid tumors with chimeric antigen receptors has yielded extraordinary results with genetically engineered T cells and the next stage in the evolution of this immunotherapy is the expression of T-cell receptors to target solid tumors,” said Laurence Cooper, MD, PhD, Chief Executive Officer of ZIOPHARM.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Hemal K. Gandhi, a CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 453779

NEW YORK, NY / ACCESSWIRE / January 30, 2017 / A combination of corporate earnings and strong performances by the manufacturers and miners helped U.S. markets post strong weekly gains during President Trump’s first week in office. The Dow Jones Industrial Average declined 0.04 percent to close at 20,093.78, up 1.33 percent for the week, while the S&P 500 Index declined 0.09 percent to close at 2,294.69, up 1.01 percent for the week. The Nasdaq rose 0.10 percent to close at a new record 5,660.78, posting a weekly gain of 1.88 percent.

Register with us now
for your free membership and gain access to our latest research reports at: RDInvesting.com

As of 104 companies in the S&P 500 Index reporting earnings through Wednesday morning approximately 70 percent have topped expectations, according to data from Thomson Reuters I/B/E/S. Earnings in the fourth quarter are forecasted to show a growth of 6.8 percent, which would be the largest growth rate seen in two years.

Intel Corporation (NASDAQ: INTC)

Get Your Up-To-Date Intel Research Report
Click Here

Intel’s shares gained 1.12 percent to close at $37.98 a share Friday. The stock traded between $37.81 and $38.45 on volume of 44.37 million shares traded. Driven by growth in data center business, the company reported adjusted earnings of $0.79 per share on revenues of $16.37 billion for the fourth quarter of 2016. Average analysts’ expectations had called for adjusted earnings of $0.74 a share on revenues of $15.75 billion, according to analysts surveyed by Thomson Reuters. The company expects first-quarter revenue of $14.8 billion, plus or minus $500 million. Analysts on average were expecting $14.53 billion, according to Thomson Reuters.

“In 2017 and beyond, we expect server revenue to offset declines on the PC side,” said Edward Jones analyst, Bill Kreher.

Chevron Corporation (NYSE: CVX)

Get Your Up-To-Date Chevron Research Report
Click Here

Chevron’s shares declined 2.37 percent to close at $113.79 a share Friday. The stock traded between $112.85 and $114.70 on volume of 11.70 million shares traded. The company reported earnings of $415 million, or $0.22 a share, on revenues of $31.5 billion, for the fourth quarter of 2016. Excluding onetime items, the company has generated earnings of $0.21 a share for the quarter, which fell short of consensus analysts’ estimates of earnings of $0.64 a share on revenues of $33.3 billion, according to Thomson Reuters. Capital and exploration spending totaled $22.4 billion in 2016, down from $34 billion in 2015.

“Our 2016 earnings reflect the low oil and gas prices we saw during the year,” Chairman and CEO John Watson said in a statement. “We responded aggressively to those conditions, cutting capital and operating expenses by $14 billion.”

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Hemal K. Gandhi, a CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 453787